Core Insights - Milestone Pharmaceuticals has launched its first commercial product, CARDAMYST™ (etripamil) nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, now available through U.S. retail pharmacies [2][4][8] - The FDA approved CARDAMYST on December 12, 2025, marking the first new treatment for PSVT in over 30 years [6] Product Launch and Support - CARDAMYST will be supported by a patient assistance platform that includes benefits verification, reimbursement support, and copay assistance, with copays capped at $25 for eligible commercially insured patients [3][5] - A national sales force is set to be deployed in mid-February 2026 to promote the product [2][5] Patient Impact and Market Need - Approximately two million people in the U.S. are diagnosed with PSVT, which causes episodes of rapid heartbeats and can significantly impact daily life [7] - The availability of CARDAMYST provides patients with a self-administered treatment option, allowing for on-demand care and greater control over their condition [4][8] Clinical Background - CARDAMYST is a novel calcium channel blocker designed for rapid response therapy, bypassing the need for immediate medical oversight [8] - The product has undergone a robust clinical trial program, including a completed Phase 3 clinical-stage program for PSVT [8]

Core Viewpoint - Aptar Group, Inc. has announced that its Bidose Liquid Nasal Spray System will be used for the newly approved CARDAMYST Nasal Spray, which is intended for treating acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) [1] Company Summary - Aptar Group, Inc. is recognized as a global leader in drug and consumer product dosing, dispensing, and protection technologies [1] - The Bidose Liquid Nasal Spray System is a key product in Aptar's portfolio, showcasing its capabilities in drug delivery systems [1] Industry Summary - The approval of CARDAMYST by the U.S. Food and Drug Administration (FDA) highlights advancements in treatment options for PSVT, indicating a growing market for innovative drug delivery systems [1]

FDA Approval Investor Call December 15, 2025 Forward Looking Statements The Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ''aim,'' ''anticipate,'' ''assume,'' ''believe,'' ''contemplate,'' ''continue,'' ''could,'' ''design,'' ''due,'' ''estimate,'' ''expect,'' ''goal,'' ''intend,'' ''may,'' ''objective,'' ''plan,'' ''predict,'' ''positioned,'' ''potential,'' ''project,'' ''s ...